Longeveron Inc., a clinical-stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024.
 
In this role, Blass will lead the Company’s technological and manufacturing strategies.
 
“We are delighted to have Devin join Longeveron at this transformational time in the Company’s evolution,” said Wa’el Hashad, Chief Executive Officer at Longeveron. “This appointment reinforces Longeveron’s commitment to advancing stem cell therapies as well as appropriately resourcing the Company ahead of a potential Biological License Application (BLA) submission in HLHS, should the on-going pivotal ELPIS II trial produce positive data.”
 
“I am thrilled to join Longeveron as the CTO and SVP of CMC,” said Blass. “Longeveron’s commitment to advancing regenerative medicine aligns with my passion for developing innovative therapies. I look forward to contributing to the Company’s mission and driving forward our technological and manufacturing strategies to bring transformative treatments to patients.”

Experience 

Blass has over 15 years of experience in the development and manufacture of advanced therapies. Prior to Longeveron, Blass joined the New York Blood Center (NYBC) in 2023 as the Senior Vice President of Comprehensive Cell Solutions, the contract development and manufacturing organization (CDMO) arm of New York Blood Center Enterprises (NYBCe). There, he oversaw the CDMO business unit, encompassing Technical Operations, Business Development, and Cell Sourcing.
 
Before his tenure at NYBC, Blass served as the Vice President of Technical Operations and Site Head at Talaris Therapeutics, where he managed Technical Operations and Supply Chain. His career also includes directing cell manufacturing operations at Bellicum Pharmaceuticals and serving as the Director of Commercial Program Manufacturing at Mesoblast.
 
Blass’s industry experience is complemented by his significant contributions at MD Anderson Cancer Center, where he advanced through roles of increasing responsibility. There, he played a pivotal role in developing the infrastructure and systems necessary to obtain licensure for HPC and Cord Blood.
 
Blass holds a Bachelor of Science in Biochemistry from Texas State University.